Literature DB >> 26159751

Current and emerging treatment options for Wiskott-Aldrich syndrome.

Austen J J Worth1, Adrian J Thrasher.   

Abstract

Wiskott-Aldrich syndrome is a life-threatening primary immunodeficiency associated with a bleeding tendency, eczema and a high incidence of autoimmunity and malignancy. Stem cell transplantation offers the opportunity of cure for all these complications, and over the past 35 years there has been a remarkable improvement in survival following this treatment. Here, we review advances in management of clinical complications pre- and post-transplant, as well as discuss the morbidity Wiskott-Aldrich syndrome patients experience following treatment. For patients with a poorly matched stem cell donor, recent gene therapy trials demonstrate encouraging results and the potential of low-toxicity therapy for all patients.

Entities:  

Keywords:  Wiskott Aldrich syndrome; Wiskott Aldrich syndrome protein; X-linked thrombocytopenia; allogeneic hematopoietic stem cell transplantation; autoimmunity; gene therapy; primary immunodeficiency; thrombocytopenia

Mesh:

Substances:

Year:  2015        PMID: 26159751     DOI: 10.1586/1744666X.2015.1062366

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  16 in total

Review 1.  Evolving Gene Therapy in Primary Immunodeficiency.

Authors:  Adrian J Thrasher; David A Williams
Journal:  Mol Ther       Date:  2017-03-31       Impact factor: 11.454

2.  Trends in TREC values according to age and gender in Chinese children and their clinical applications.

Authors:  Qin Zhao; Rongxin Dai; Yanan Li; Yanping Wang; Xuemei Chen; Zhou Shu; Lina Zhou; Yuan Ding; Xuemei Tang; Xiaodong Zhao
Journal:  Eur J Pediatr       Date:  2021-08-17       Impact factor: 3.183

Review 3.  Primary Immune Deficiency Treatment Consortium (PIDTC) update.

Authors:  Linda M Griffith; Morton J Cowan; Luigi D Notarangelo; Donald B Kohn; Jennifer M Puck; William T Shearer; Lauri M Burroughs; Troy R Torgerson; Hélène Decaluwe; Elie Haddad
Journal:  J Allergy Clin Immunol       Date:  2016-04-22       Impact factor: 10.793

4.  Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult.

Authors:  Emma C Morris; Thomas Fox; Ronjon Chakraverty; Rita Tendeiro; Katie Snell; Christine Rivat; Sarah Grace; Kimberly Gilmour; Sarita Workman; Karen Buckland; Katie Butler; Ronnie Chee; Alan D Salama; Hazem Ibrahim; Havinder Hara; Cecile Duret; Fulvio Mavilio; Frances Male; Frederick D Bushman; Anne Galy; Siobhan O Burns; H Bobby Gaspar; Adrian J Thrasher
Journal:  Blood       Date:  2017-07-17       Impact factor: 22.113

5.  Wiskott-Aldrich syndrome gene mutations modulate cancer susceptibility in the p53± murine model.

Authors:  Marton Keszei; Joanna S Kritikou; Deborah Sandfort; Minghui He; Mariana M S Oliveira; Hannah Wurzer; Raoul V Kuiper; Lisa S Westerberg
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

Review 6.  Congenital Defects in Actin Dynamics of Germinal Center B Cells.

Authors:  Minghui He; Lisa S Westerberg
Journal:  Front Immunol       Date:  2019-03-06       Impact factor: 7.561

7.  When WAS Gene Diagnosis Is Needed: Seeking Clues Through Comparison Between Patients With Wiskott-Aldrich Syndrome and Idiopathic Thrombocytopenic Purpura.

Authors:  Ying-Ying Jin; Jing Wu; Tong-Xin Chen; Ji Chen
Journal:  Front Immunol       Date:  2019-07-09       Impact factor: 7.561

8.  Wiskott Aldrich syndrome protein regulates non-selective autophagy and mitochondrial homeostasis in human myeloid cells.

Authors:  Elizabeth Rivers; Rajeev Rai; Jonas Lötscher; Michael Hollinshead; Gasper Markelj; James Thaventhiran; Austen Worth; Alessia Cavazza; Christoph Hess; Mona Bajaj-Elliott; Adrian J Thrasher
Journal:  Elife       Date:  2020-11-02       Impact factor: 8.140

Review 9.  Wiskott-Aldrich Syndrome (WAS) and Dedicator of Cytokinesis 8- (DOCK8) Deficiency.

Authors:  Michael H Albert; Alexandra F Freeman
Journal:  Front Pediatr       Date:  2019-11-05       Impact factor: 3.418

Review 10.  Gene Editing for the Treatment of Primary Immunodeficiency Diseases.

Authors:  Rajeev Rai; Adrian J Thrasher; Alessia Cavazza
Journal:  Hum Gene Ther       Date:  2020-10-16       Impact factor: 4.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.